Want some further information about HTLV, try some of the following links:

Clinical Trial Update on HAM/TSP

1)     HAMLET-P: HTLV-1 Associated myelopathy/tropical spastic Paraparesis Multicentre Exploratory Double Blind Randomised Trial of Prednisolone (HAMLET-P).

This is a multi-centre international collaborative trial between Japan, Brazil, UK and USA.

Japan Trial site has started recruitment. 
The primary aim of this multicenter international Phase II study is to identify whether or not steroids are an effective therapy in the treatment of HAM/TSP.   
  • Ambulant adults with definite HAM/TSP categorised into one of the three different subtypes of HAM/TSP are recruited. 
  • Arm A) A double blind placebo controlled trial of prednisolone vs placebo in patients with slow progressing HAM/TSP.
  • Arm B) Open label head to head comparison of oral prednisolone versus i.v. methylprednisolone in patients with rapidly progressing HAM/TSP.
  • Arm C) Non-interventional, observational study arm of patients with non progressing HAM/TSP to collect collect the same immunological, virological and clinical data for 48 weeks in comparison to Arms A+B.
The primary outcome measure of Arms A + B is the change from baseline in 10 meter timed walk at 24 weeks.
  • Secondary outcomes for all three studies will include clinical, safety, radiological, virological and immunological measures. 

Further two clinical trials are currently recruiting in Japan only:
 
2)     Anti-CCR4 antibody trial in HAM/TSP patients: Ambulant HAM/TSP not responding to oral prednisolone treatment receive add on anti-CCR4 antibody treatment.
 
3)     HAL- HAM/TSP: Patients with advanced disability are provided with the exoskeleton robot suit termed HAL to improve mobility and rebuild muscle strength.
PictureTweet us!
Social Media:
TwitterFacebookBlogs
Other
Look for any available trials:
Some interesting papers:

Home- What is HTLV? HTLV-1, HTLV-2, Diagnosis Asymptomatic Carrier HAM/TSP, ATLL Other Associated Diseases
Simple Science Contact Us, Further Information
Please join us! Follow us on Twitter and tweet. Send us emails:  we promise to answer. Become an active partner of HTLVAware! Do you like to blog? Send us pictures? Tell us your stories?
We felt that too many patients with HTLV and their relatives, too many clinicians and scientists did not know what HTLV was. We felt that everybody has the right to quick, accurate and easily accessible information online, but especially people who are suffering with HTLV and those who care for them.